Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic

The majority of breast cancers express the estrogen receptor (ER) and for this group of patients, endocrine therapy is the cornerstone of systemic treatment. However, drug resistance is common and a focus for breast cancer preclinical and clinical research. Over the past 2 decades, the PI3K/Akt/mTOR...

Descripción completa

Detalles Bibliográficos
Autores principales: Skolariki, Aglaia, D’Costa, Jamie, Little, Martin, Lord, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Open Exploration 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400772/
https://www.ncbi.nlm.nih.gov/pubmed/36046843
http://dx.doi.org/10.37349/etat.2022.00078

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400772/
https://www.ncbi.nlm.nih.gov/pubmed/36046843
http://dx.doi.org/10.37349/etat.2022.00078

Ejemplares similares